Morgan Stanley
ADPT icon

Morgan Stanley’s Adaptive Biotechnologies ADPT Stock Holding History

Morgan Stanley’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4M Sell
766,230
-200,890
-21% -$3.08M ﹤0.01% 3273
2026
Q1 		$13.4M Sell
967,120
-181,962
-16% -$2.9M ﹤0.01% 3311
2025
Q4 		$18.7M Buy
1,149,082
+77,012
+7% +$1.26M ﹤0.01% 3007
2025
Q3 		$16M Sell
1,072,070
-225,874
-17% -$2.75M ﹤0.01% 3098
2025
Q2 		$15.1M Buy
1,297,944
+172,683
+15% +$1.57M ﹤0.01% 3074
2025
Q1 		$8.36M Sell
1,125,261
-68,574
-6% -$527K ﹤0.01% 3505
2024
Q4 		$7.16M Buy
1,193,835
+145,703
+14% +$803K ﹤0.01% 3684
2024
Q3 		$5.37M Buy
1,048,132
+531,672
+103% +$2.32M ﹤0.01% 3907
2024
Q2 		$1.87M Sell
516,460
-152,670
-23% -$485K ﹤0.01% 4613
2024
Q1 		$2.15M Sell
669,130
-274,669
-29% -$1.06M ﹤0.01% 4531
2023
Q4 		$4.62M Buy
943,799
+539,016
+133% +$2.46M ﹤0.01% 3981
2023
Q3 		$2.21M Sell
404,783
-255,730
-39% -$1.69M ﹤0.01% 4331
2023
Q2 		$4.43M Sell
660,513
-53,409
-7% -$397K ﹤0.01% 3866
2023
Q1 		$6.3M Sell
713,922
-693,768
-49% -$6.12M ﹤0.01% 3579
2022
Q4 		$10.8M Buy
1,407,690
+386,229
+38% +$3M ﹤0.01% 3010
2022
Q3 		$7.27M Sell
1,021,461
-125,905
-11% -$1.19M ﹤0.01% 3305
2022
Q2 		$9.28M Buy
1,147,366
+640,112
+126% +$5.63M ﹤0.01% 3137
2022
Q1 		$7.04M Buy
507,254
+115,575
+30% +$1.82M ﹤0.01% 3310
2021
Q4 		$11M Sell
391,679
-72,950
-16% -$2.24M ﹤0.01% 2850
2021
Q3 		$15.8M Sell
464,629
-29,194
-6% -$1.06M ﹤0.01% 2347
2021
Q2 		$20.2M Sell
493,823
-102,969
-17% -$4M ﹤0.01% 2137
2021
Q1 		$24M Buy
596,792
+170,882
+40% +$9.25M ﹤0.01% 1745
2020
Q4 		$25.2M Buy
425,910
+128,564
+43% +$6.63M ﹤0.01% 1594
2020
Q3 		$14.5M Buy
297,346
+83,804
+39% +$3.52M ﹤0.01% 1713
2020
Q2 		$10.3M Sell
213,542
-10,840
-5% -$395K ﹤0.01% 1934
2020
Q1 		$6.23M Buy
224,382
+11,993
+6% +$335K ﹤0.01% 2238
2019
Q4 		$6.36M Buy
212,389
+41,216
+24% +$1.18M ﹤0.01% 2921
2019
Q3 		$5.29M Buy
171,173
+20,086
+13% +$820K ﹤0.01% 2824
2019
Q2 		$7.3M Buy
+151,087
New +$6.69M ﹤0.01% 2507

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley's ADPT Position: Q2 2026 in Review

Morgan Stanley reduced its Adaptive Biotechnologies (ADPT) stake by 21% in Q2 2026, selling an estimated $3.08M and leaving 766,230 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3273.

Morgan Stanley first reported a position in ADPT in Q2 2019 and has held it in 29 quarters since. The position peaked at $25.2M in Q4 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Morgan Stanley held 766,230 shares of Adaptive Biotechnologies worth $16.4M as of Q2 2026.
  • Morgan Stanley sold 200,890 Adaptive Biotechnologies shares in Q2 2026, an estimated $3.08M.
  • Adaptive Biotechnologies made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3273 holding.
  • Morgan Stanley first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 29 quarters since.
  • Morgan Stanley's Adaptive Biotechnologies position peaked at $25.2M in Q4 2020.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.